{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:38:38Z","timestamp":1792226318060,"version":"4.4.0"},"reference-count":314,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T00:00:00Z","timestamp":1699228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Croatian Science Foundation","award":["IP-2019-04-6100"],"award-info":[{"award-number":["IP-2019-04-6100"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Dementia is a syndrome of global and progressive deterioration of cognitive skills, especially memory, learning, abstract thinking, and orientation, usually affecting the elderly. The most common forms are Alzheimer\u2019s disease, vascular dementia, and other (frontotemporal, Lewy body disease) dementias. The etiology of these multifactorial disorders involves complex interactions of various environmental and (epi)genetic factors and requires multiple forms of pharmacological intervention, including anti-dementia drugs for cognitive impairment, antidepressants, antipsychotics, anxiolytics and sedatives for behavioral and psychological symptoms of dementia, and other drugs for comorbid disorders. The pharmacotherapy of dementia patients has been characterized by a significant interindividual variability in drug response and the development of adverse drug effects. The therapeutic response to currently available drugs is partially effective in only some individuals, with side effects, drug interactions, intolerance, and non-compliance occurring in the majority of dementia patients. Therefore, understanding the genetic basis of a patient\u2019s response to pharmacotherapy might help clinicians select the most effective treatment for dementia while minimizing the likelihood of adverse reactions and drug interactions. Recent advances in pharmacogenomics may contribute to the individualization and optimization of dementia pharmacotherapy by increasing its efficacy and safety via a prediction of clinical outcomes. Thus, it can significantly improve the quality of life in dementia patients.<\/jats:p>","DOI":"10.3390\/genes14112048","type":"journal-article","created":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T13:24:53Z","timestamp":1699277093000},"page":"2048","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Pharmacogenomics of Dementia: Personalizing the Treatment of Cognitive and Neuropsychiatric Symptoms"],"prefix":"10.3390","volume":"14","author":[{"given":"Barbara","family":"Vuic","sequence":"first","affiliation":[{"name":"Laboratory for Molecular Neuropsychiatry, Division of Molecular Medicine, Rudjer Boskovic Institute, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Milos","sequence":"additional","affiliation":[{"name":"Laboratory for Molecular Neuropsychiatry, Division of Molecular Medicine, Rudjer Boskovic Institute, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9125-406X","authenticated-orcid":false,"given":"Lucija","family":"Tudor","sequence":"additional","affiliation":[{"name":"Laboratory for Molecular Neuropsychiatry, Division of Molecular Medicine, Rudjer Boskovic Institute, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3113-0778","authenticated-orcid":false,"given":"Matea","family":"Nikolac Perkovic","sequence":"additional","affiliation":[{"name":"Laboratory for Molecular Neuropsychiatry, Division of Molecular Medicine, Rudjer Boskovic Institute, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Konjevod","sequence":"additional","affiliation":[{"name":"Laboratory for Molecular Neuropsychiatry, Division of Molecular Medicine, Rudjer Boskovic Institute, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0787-9340","authenticated-orcid":false,"given":"Gordana","family":"Nedic Erjavec","sequence":"additional","affiliation":[{"name":"Laboratory for Molecular Neuropsychiatry, Division of Molecular Medicine, Rudjer Boskovic Institute, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Farkas","sequence":"additional","affiliation":[{"name":"Laboratory for Molecular Neuropsychiatry, Division of Molecular Medicine, Rudjer Boskovic Institute, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzana","family":"Uzun","sequence":"additional","affiliation":[{"name":"Department for Biological Psychiatry and Psychogeriatry, University Hospital Vrapce, 10000 Zagreb, Croatia"},{"name":"School of Medicine, University of Zagreb, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4552-0547","authenticated-orcid":false,"given":"Ninoslav","family":"Mimica","sequence":"additional","affiliation":[{"name":"Department for Biological Psychiatry and Psychogeriatry, University Hospital Vrapce, 10000 Zagreb, Croatia"},{"name":"School of Medicine, University of Zagreb, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6200-2405","authenticated-orcid":false,"given":"Dubravka","family":"Svob Strac","sequence":"additional","affiliation":[{"name":"Laboratory for Molecular Neuropsychiatry, Division of Molecular Medicine, Rudjer Boskovic Institute, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/978-1-62703-758-7_17","article-title":"Sources of Interindividual Variability","volume":"1113","author":"Thummel","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"895","DOI":"10.2217\/14622416.9.7.895","article-title":"Pharmacogenomics and Treatment for Dementia Induced by Alzheimer\u2019s Disease","volume":"9","author":"Gupta","year":"2008","journal-title":"Pharmacogenomics"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1146\/annurev.genom.3.022502.103022","article-title":"Deciphering the Genetic Basis of Alzheimer\u2019s Disease","volume":"3","author":"Selkoe","year":"2002","journal-title":"Annu. Rev. Genom. Hum. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s00406-007-1006-x","article-title":"Pharmacogenomics and Therapeutic Prospects in Dementia","volume":"258","author":"Cacabelos","year":"2008","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"ref_5","first-page":"151","article-title":"Pharmacogenomics of Alzheimer\u2019s Disease: Genetic Determinants of Phenotypic Variation and Therapeutic Outcome","volume":"1","author":"Cacabelos","year":"2016","journal-title":"J. Genom. Med. Pharmacogenom."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1001\/jama.2019.4782","article-title":"Diagnosis and Management of Dementia: Review","volume":"322","author":"Arvanitakis","year":"2019","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/1715163517690745","article-title":"Dementia: What Pharmacists Need to Know","volume":"150","author":"Duong","year":"2017","journal-title":"Can. Pharm. J."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Cacabelos, R. (2020). Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21093059"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","article-title":"Estimation of the Global Prevalence of Dementia in 2019 and Forecasted Prevalence in 2050: An Analysis for the Global Burden of Disease Study 2019","volume":"7","author":"Nichols","year":"2022","journal-title":"Lancet Public Health"},{"key":"ref_10","first-page":"518901","article-title":"Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics","volume":"2012","author":"Cacabelos","year":"2012","journal-title":"Int. J. Alzheimer\u2019s Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1474-4422(12)70307-1","article-title":"A Presenilin 1 Mutation in the First Case of Alzheimer\u2019s Disease","volume":"12","author":"Winter","year":"2013","journal-title":"Lancet Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/ene.13439","article-title":"Alzheimer\u2019s Disease","volume":"25","author":"Lane","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.5114\/fn.2019.85929","article-title":"Risk Factors for Alzheimer\u2019s Disease","volume":"57","author":"Armstrong","year":"2019","journal-title":"Folia Neuropathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.biopsych.2014.05.006","article-title":"Alzheimer\u2019s Disease Risk Genes and Mechanisms of Disease Pathogenesis","volume":"77","author":"Karch","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41588-018-0311-9","article-title":"Genome-Wide Meta-Analysis Identifies New Loci and Functional Pathways Influencing Alzheimer\u2019s Disease Risk","volume":"51","author":"Jansen","year":"2019","journal-title":"Nat. Genet."},{"key":"ref_16","unstructured":"Sheppard, O., and Coleman, M. (2020). Alzheimer\u2019s Disease: Drug Discovery, Exon Publications."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.cger.2014.04.001","article-title":"Dementia and Cognitive Impairment","volume":"30","author":"Hugo","year":"2014","journal-title":"Clin. Geriatr. Med."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2008.03.006","article-title":"Morphologic Diagnosis of \u201cVascular Dementia\u201d\u2014A Critical Update","volume":"270","author":"Jellinger","year":"2008","journal-title":"J. Neurol. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1474-4422(09)70127-9","article-title":"CADASIL","volume":"8","author":"Chabriat","year":"2009","journal-title":"Lancet Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1042\/CS20160607","article-title":"Clinical Presentations and Epidemiology of Vascular Dementia","volume":"131","author":"Smith","year":"2017","journal-title":"Clin. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/JGP.0b013e318202fc8a","article-title":"The Vascular Depression Hypothesis: An Update","volume":"19","author":"Sneed","year":"2011","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Jellinger, K.A., and Korczyn, A.D. (2018). Are Dementia with Lewy Bodies and Parkinson\u2019s Disease Dementia the Same Disease?. BMC Med., 16.","DOI":"10.1186\/s12916-018-1016-8"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","article-title":"Diagnosis and Management of Dementia with Lewy Bodies: Third Report of the DLB Consortium","volume":"65","author":"McKeith","year":"2005","journal-title":"Neurology"},{"key":"ref_25","unstructured":"Haider, A., Spurling, B.C., and S\u00e1nchez-Manso, J.C. (2023). StatPearls [Internet], StatPearls Publishing."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1134\/S0026893320010136","article-title":"Genetic Diversity in Frontotemporal Dementia","volume":"54","author":"Shpilyukova","year":"2020","journal-title":"Mol. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3109\/09540261.2013.776523","article-title":"The Epidemiology of Frontotemporal Dementia","volume":"25","author":"Onyike","year":"2013","journal-title":"Int. Rev. Psychiatry"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3233\/JAD-170584","article-title":"Biological, Neuroimaging, and Neurophysiological Markers in Frontotemporal Dementia: Three Faces of the Same Coin","volume":"62","author":"Borroni","year":"2018","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1177\/1039856219860031","article-title":"Heterogeneity in the Psychiatric Presentation of Behavioural Variant Frontotemporal Dementia (BvFTD)","volume":"27","author":"Gallur","year":"2019","journal-title":"Australas. Psychiatry"},{"key":"ref_30","unstructured":"Khan, I., and De Jesus, O. (2023). StatPearls [Internet], StatPearls Publishing."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2165\/11533100-000000000-00000","article-title":"Frontotemporal Lobar Degeneration","volume":"24","author":"Rabinovici","year":"2010","journal-title":"CNS Drugs"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1007\/s00415-022-11512-1","article-title":"Language Impairment in the Genetic Forms of Behavioural Variant Frontotemporal Dementia","volume":"270","author":"Samra","year":"2023","journal-title":"J. Neurol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S0140-6736(13)60630-3","article-title":"Genetics of Dementia","volume":"383","author":"Loy","year":"2014","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1073905","DOI":"10.3389\/fnagi.2022.1073905","article-title":"The Role of Structural Variations in Alzheimer\u2019s Disease and Other Neurodegenerative Diseases","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Aging Neurosci."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Nikolac Perkovic, M., Videtic Paska, A., Konjevod, M., Kouter, K., Svob Strac, D., Nedic Erjavec, G., and Pivac, N. (2021). Epigenetics of Alzheimer\u2019s Disease. Biomolecules, 11.","DOI":"10.3390\/biom11020195"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s13311-021-01152-0","article-title":"Genomics and Functional Genomics of Alzheimer\u2019s Disease","volume":"19","author":"Kamboh","year":"2022","journal-title":"Neurotherapeutics"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.ajhg.2018.04.002","article-title":"The Post-GWAS Era: From Association to Function","volume":"102","author":"Gallagher","year":"2018","journal-title":"Am. J. Hum. Genet."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"eabi8654","DOI":"10.1126\/science.abi8654","article-title":"Functional Regulatory Variants Implicate Distinct Transcriptional Networks in Dementia","volume":"377","author":"Cooper","year":"2022","journal-title":"Science"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/archneurol.2011.221","article-title":"Autosomal Recessive Causes Likely in Early-Onset Alzheimer Disease","volume":"69","author":"Wingo","year":"2012","journal-title":"Arch. Neurol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1001\/archpsyc.63.2.168","article-title":"Role of Genes and Environments for Explaining Alzheimer Disease","volume":"63","author":"Gatz","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrneurol.2009.218","article-title":"The Secretases: Enzymes with Therapeutic Potential in Alzheimer Disease","volume":"6","author":"Vassar","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1177\/1533317514545825","article-title":"The Patterns of Inheritance in Early-Onset Dementia: Alzheimer\u2019s Disease and Frontotemporal Dementia","volume":"30","author":"Jarmolowicz","year":"2015","journal-title":"Am. J. Alzheimer\u2019s Dis. Other Demen."},{"key":"ref_43","first-page":"195","article-title":"Apolipoprotein E Polymorphism and Susceptibility to Alzheimer\u2019s Disease","volume":"67","author":"Kamboh","year":"1995","journal-title":"Hum. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","article-title":"Alzheimer Disease: An Update on Pathobiology and Treatment Strategies","volume":"179","author":"Long","year":"2019","journal-title":"Cell"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Lumsden, A.L., Mulugeta, A., Zhou, A., and Hypp\u00f6nen, E. (2020). Apolipoprotein E (APOE) Genotype-Associated Disease Risks: A Phenome-Wide, Registry-Based, Case-Control Study Utilising the UK Biobank. EBioMedicine, 59.","DOI":"10.1016\/j.ebiom.2020.102954"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00109-016-1427-y","article-title":"Apolipoprotein E: From Cardiovascular Disease to Neurodegenerative Disorders","volume":"94","author":"Mahley","year":"2016","journal-title":"J. Mol. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1750-1326-9-11","article-title":"ApoE Variant p.V236E Is Associated with Markedly Reduced Risk of Alzheimer\u2019s Disease","volume":"9","author":"Medway","year":"2014","journal-title":"Mol. Neurodegener."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e622","DOI":"10.1212\/NXG.0000000000000622","article-title":"Integrative Network-Based Analysis Reveals Gene Networks and Novel Drug Repositioning Candidates for Alzheimer Disease","volume":"7","author":"Gerring","year":"2021","journal-title":"Neurol. Genet."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1126\/science.aay0793","article-title":"Brain Cell Type\u2014Specific Enhancer\u2014Promoter Interactome Maps and Disease-Risk Association","volume":"366","author":"Alexi","year":"2019","journal-title":"Science"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jalz.2014.05.1757","article-title":"Convergent Genetic and Expression Data Implicate Immunity in Alzheimer\u2019s Disease","volume":"11","author":"Jones","year":"2015","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41593-022-01031-7","article-title":"Integrating Whole-Genome Sequencing with Multi-Omic Data Reveals the Impact of Structural Variants on Gene Regulation in the Human Brain","volume":"25","author":"Vialle","year":"2022","journal-title":"Nat. Neurosci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1002\/alz.12507","article-title":"Whole Genome Sequencing\u2013Based Copy Number Variations Reveal Novel Pathways and Targets in Alzheimer\u2019s Disease","volume":"18","author":"Ming","year":"2022","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3233\/JAD-2012-121285","article-title":"Genome-Wide Scan for Copy Number Variation Association with Age at Onset of Alzheimer\u2019s Disease","volume":"33","author":"Szigeti","year":"2013","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/mp.2015.121","article-title":"SORL1 Rare Variants: A Major Risk Factor for Familial Early-Onset Alzheimer\u2019s Disease","volume":"21","author":"Nicolas","year":"2016","journal-title":"Mol. Psychiatry"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/ng.439","article-title":"Genome-Wide Association Study Identifies Variants at CLU and CR1 Associated with Alzheimer\u2019s Disease","volume":"41","author":"Lambert","year":"2009","journal-title":"Nat. Genet."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/ng.440","article-title":"Genome-Wide Association Study Identifies Variants at CLU and PICALM Associated with Alzheimer\u2019s Disease","volume":"41","author":"Harold","year":"2009","journal-title":"Nat. Genet."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.neuron.2013.08.035","article-title":"ADAM10 Missense Mutations Potentiate \u03b2-Amyloid Accumulation by Impairing Prodomain Chaperone Function","volume":"80","author":"Suh","year":"2013","journal-title":"Neuron"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/mp.2013.1","article-title":"Increased Expression of BIN1 Mediates Alzheimer Genetic Risk by Modulating Tau Pathology","volume":"18","author":"Chapuis","year":"2013","journal-title":"Mol. Psychiatry"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40478-021-01285-5","article-title":"The Alzheimer Susceptibility Gene BIN1 Induces Isoform-Dependent Neurotoxicity through Early Endosome Defects","volume":"10","author":"Lambert","year":"2022","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1016\/j.neurobiolaging.2013.05.001","article-title":"Insights into TREM2 Biology by Network Analysis of Human Brain Gene Expression Data","volume":"34","author":"Forabosco","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3389\/fncel.2019.00374","article-title":"Lack of Neuronal Glycogen Impairs Memory Formation and Learning-Dependent Synaptic Plasticity in Mice","volume":"13","author":"Duran","year":"2019","journal-title":"Front. Cell. Neurosci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13195-020-00726-y","article-title":"Alpha-Amylase 1A Copy Number Variants and the Association with Memory Performance and Alzheimer\u2019s Dementia","volume":"12","author":"Byman","year":"2020","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00401-019-01994-1","article-title":"The Role of ABCA7 in Alzheimer\u2019s Disease: Evidence from Genomics, Transcriptomics and Methylomics","volume":"138","author":"Sleegers","year":"2019","journal-title":"Acta Neuropathol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e111065","DOI":"10.15252\/embj.2022111065","article-title":"Cryo-EM Structures of Human ABCA7 Provide Insights into Its Phospholipid Translocation Mechanisms","volume":"42","author":"Le","year":"2023","journal-title":"EMBO J."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jalz.2017.01.017","article-title":"The Alu Neurodegeneration Hypothesis: A Primate-Specific Mechanism for Neuronal Transcription Noise, Mitochondrial Dysfunction, and Manifestation of Neurodegenerative Disease","volume":"13","author":"Larsen","year":"2017","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Chen, S., Sarasua, S.M., Davis, N.J., DeLuca, J.M., Boccuto, L., Thielke, S.M., and Yu, C.E. (2022). TOMM40 Genetic Variants Associated with Healthy Aging and Longevity: A Systematic Review. BMC Geriatr., 22.","DOI":"10.1186\/s12877-022-03337-4"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.cell.2009.08.005","article-title":"Importing Mitochondrial Proteins: Machineries and Mechanisms","volume":"138","author":"Chacinska","year":"2009","journal-title":"Cell"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1016\/j.bbadis.2017.07.031","article-title":"The Biological Foundation of the Genetic Association of TOMM40 with Late-Onset Alzheimer\u2019s Disease","volume":"1863","author":"Zeitlow","year":"2017","journal-title":"Biochim. Biophys. Acta-Mol. Basis Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/tpj.2017.4","article-title":"Sulfotransferase 1A3\/4 Copy Number Variation Is Associated with Neurodegenerative Disease","volume":"18","author":"Butcher","year":"2018","journal-title":"Pharmacogenom. J."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1161\/STR.0b013e3182299496","article-title":"Vascular Contributions to Cognitive Impairment and Dementia: A Statement for Healthcare Professionals from the American Heart Association\/American Stroke Association","volume":"42","author":"Gorelick","year":"2011","journal-title":"Stroke"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Ikram, M.A., Bersano, A., Manso-Calder\u00f3n, R., Jia, J.-P., Schmidt, H., Middleton, L., Nacmias, B., Siddiqi, S., and Adams, H.H.H. (2017). Genetics of Vascular Dementia\u2014Review from the ICVD Working Group. BMC Med., 15.","DOI":"10.1186\/s12916-017-0813-9"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"FNL5","DOI":"10.2217\/fnl-2018-0027","article-title":"Genetics in Vascular Dementia","volume":"14","year":"2019","journal-title":"Future Neurol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1586\/14737159.2014.922880","article-title":"Interpretation of NOTCH3 Mutations in the Diagnosis of CADASIL","volume":"14","author":"Rutten","year":"2014","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jstrokecerebrovasdis.2010.11.008","article-title":"Cerebral Autosomal Recessive Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CARASIL): From Discovery to Gene Identification","volume":"20","author":"Fukutake","year":"2011","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-146-6-200703200-00007","article-title":"Narrative Review: Fabry Disease","volume":"146","author":"Clarke","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/ng2082","article-title":"C-Terminal Truncations in Human 3\u2032-5\u2032 DNA Exonuclease TREX1 Cause Autosomal Dominant Retinal Vasculopathy with Cerebral Leukodystrophy","volume":"39","author":"Richards","year":"2007","journal-title":"Nat. Genet."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00401-009-0501-8","article-title":"Genetics and Molecular Pathogenesis of Sporadic and Hereditary Cerebral Amyloid Angiopathies","volume":"118","author":"Revesz","year":"2009","journal-title":"Acta Neuropathol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1042\/CS20160825","article-title":"New Insights into Mechanisms of Small Vessel Disease Stroke from Genetics","volume":"131","author":"Tan","year":"2017","journal-title":"Clin. Sci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3233\/JAD-143102","article-title":"Genetics of Vascular Dementia: Systematic Review and Meta-Analysis","volume":"46","author":"Sun","year":"2015","journal-title":"J. Alzheime\u2019rs Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.neulet.2003.12.100","article-title":"Paraoxonase 1 Gene Polymorphisms and Dementia in Humans","volume":"358","author":"Helbecque","year":"2004","journal-title":"Neurosci. Lett."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1177\/0891988708328221","article-title":"Association of ACE I\/D Gene Polymorphism with Vascular Dementia: A Meta-Analysis","volume":"22","author":"Liu","year":"2009","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.gene.2012.03.010","article-title":"Genetic Association of the Gene Encoding RPGRIP1L with Susceptibility to Vascular Dementia","volume":"499","author":"Woo","year":"2012","journal-title":"Gene"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3109\/15622975.2011.559272","article-title":"Association of Intronic Sequence Variant in the Gene Encoding Spleen Tyrosine Kinase with Susceptibility to Vascular Dementia","volume":"14","author":"Kim","year":"2013","journal-title":"World J. Biol. Psychiatry"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3109\/15622975.2011.630407","article-title":"Functions of Intronic Nucleotide Variants in the Gene Encoding Pleckstrin Homology like Domain Beta 2 (PHLDB2) on Susceptibility to Vascular Dementia","volume":"14","author":"Eom","year":"2013","journal-title":"World J. Biol. Psychiatry"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1007\/s00415-019-09363-4","article-title":"An Update on Genetic Frontotemporal Dementia","volume":"266","author":"Greaves","year":"2019","journal-title":"J. Neurol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1177\/0891988710383574","article-title":"Genetic Causes of Frontotemporal Degeneration","volume":"23","author":"See","year":"2010","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neuron.2011.09.011","article-title":"Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS","volume":"72","author":"Mackenzie","year":"2011","journal-title":"Neuron"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/brain\/awr361","article-title":"Frontotemporal Dementia with the C9ORF72 Hexanucleotide Repeat Expansion: Clinical, Neuroanatomical and Neuropathological Features","volume":"135","author":"Mahoney","year":"2012","journal-title":"Brain"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"661447","DOI":"10.3389\/fncel.2021.661447","article-title":"C9ORF72: What It Is, What It Does, and Why It Matters","volume":"15","author":"Smeyers","year":"2021","journal-title":"Front. Cell. Neurosci."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.bbadis.2004.06.018","article-title":"Tau Alteration and Neuronal Degeneration in Tauopathies: Mechanisms and Models","volume":"1739","author":"Brandt","year":"2005","journal-title":"Biochim. Biophys. Acta-Mol. Basis Dis."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/archneur.59.6.935","article-title":"Association between the Extended Tau Haplotype and Frontotemporal Dementia","volume":"59","author":"Verpillat","year":"2002","journal-title":"Arch. Neurol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/hmg\/8.4.711","article-title":"Association of an Extended Haplotype in the Tau Gene with Progressive Supranuclear Palsy","volume":"8","author":"Baker","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1001\/archneurol.2009.328","article-title":"The Spectrum of Mutations in Progranulin","volume":"67","author":"Yu","year":"2010","journal-title":"Arch. Neurol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/nature05016","article-title":"Mutations in Progranulin Cause Tau-Negative Frontotemporal Dementia Linked to Chromosome 17","volume":"442","author":"Baker","year":"2006","journal-title":"Nature"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1093\/hmg\/ddl241","article-title":"Mutations in Progranulin Are a Major Cause of Ubiquitin-Positive Frontotemporal Lobar Degeneration","volume":"15","author":"Gass","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1212\/WNL.0000000000002220","article-title":"Loss of TBK1 Is a Frequent Cause of Frontotemporal Dementia in a Belgian Cohort","volume":"85","author":"Gijselinck","year":"2015","journal-title":"Neurology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.4049\/jimmunol.1000262","article-title":"TANK-Binding Kinase 1 Attenuates PTAP-Dependent Retroviral Budding through Targeting Endosomal Sorting Complex Required for Transport-I","volume":"186","author":"Da","year":"2011","journal-title":"J. Immunol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11910-016-0707-9","article-title":"Genetics of Frontotemporal Dementia","volume":"16","author":"Olszewska","year":"2016","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.neurobiolaging.2015.06.005","article-title":"A Genome-Wide Screening and SNPs-to-Genes Approach to Identify Novel Genetic Risk Factors Associated with Frontotemporal Dementia","volume":"36","author":"Ferrari","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.bbrc.2019.03.124","article-title":"Long Non-Coding RNA LOC730100 Enhances Proliferation and Invasion of Glioma Cells through Competitively Sponging MiR-760 from FOXA1 MRNA","volume":"512","author":"Li","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_101","first-page":"4770","article-title":"The Centriolar Satellite Protein Cep131 Is Important for Genome Stability","volume":"125","author":"Staples","year":"2012","journal-title":"J. Cell Sci."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1083\/jcb.201111049","article-title":"Multivariate Proteomic Profiling Identifies Novel Accessory Proteins of Coated Vesicles","volume":"197","author":"Borner","year":"2012","journal-title":"J. Cell Biol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.nbd.2019.04.004","article-title":"Heritability and Genetic Variance of Dementia with Lewy Bodies","volume":"127","author":"Guerreiro","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11910-018-0874-y","article-title":"The Genetics of Dementia with Lewy Bodies: Current Understanding and Future Directions","volume":"18","author":"Orme","year":"2018","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Guo, P., Gong, W., Li, Y., Liu, L., Yan, R., Wang, Y., Zhang, Y., and Yuan, Z. (2022). Pinpointing Novel Risk Loci for Lewy Body Dementia and the Shared Genetic Etiology with Alzheimer\u2019s Disease and Parkinson\u2019s Disease: A Large-Scale Multi-Trait Association Analysis. BMC Med., 20.","DOI":"10.1186\/s12916-022-02404-2"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1474-4422(17)30400-3","article-title":"Investigating the Genetic Architecture of Dementia with Lewy Bodies: A Two-Stage Genome-Wide Association Study","volume":"17","author":"Guerreiro","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.8346443","article-title":"Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer\u2019s Disease in Late Onset Families","volume":"261","author":"Corder","year":"1993","journal-title":"Science"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.nbd.2012.02.002","article-title":"A Large Study Reveals No Association between APOE and Parkinson\u2019s Disease","volume":"46","author":"Federoff","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3233\/JAD-2003-5206","article-title":"Apolipoprotein E \u03954 in an Autopsy Series of Various Dementing Disorders","volume":"5","author":"Nielsen","year":"2003","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1212\/01.WNL.0000127517.33208.F4","article-title":"\u03b1-Synuclein in Blood and Brain from Familial Parkinson Disease with SNCA Locus Triplication","volume":"62","author":"Miller","year":"2004","journal-title":"Neurology"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/pcn.12462","article-title":"DNA Methylation Changes at SNCA Intron 1 in Patients with Dementia with Lewy Bodies","volume":"71","author":"Funahashi","year":"2017","journal-title":"Psychiatry Clin. Neurosci."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1111\/febs.14393","article-title":"The Role of Glucocerebrosidase in Parkinson Disease Pathogenesis","volume":"285","author":"Gegg","year":"2018","journal-title":"FEBS J."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/ajmg.b.32549","article-title":"Glucocerebrosidase Mutations and Neuropsychiatric Phenotypes in Parkinson\u2019s Disease and Lewy Body Dementias: Review and Meta-Analyses","volume":"177","author":"Creese","year":"2018","journal-title":"Am. J. Med. Genet. Part B Neuropsychiatr. Genet."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1073\/pnas.1616332114","article-title":"TMEM175 Deficiency Impairs Lysosomal and Mitochondrial Function and Increases \u03b1-Synuclein Aggregation","volume":"114","author":"Jinn","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/glia.23920","article-title":"Extracellular Clusterin Limits the Uptake of \u03b1-Synuclein Fibrils by Murine and Human Astrocytes","volume":"69","author":"Filippini","year":"2021","journal-title":"Glia"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/ni.2341","article-title":"F-Box Protein FBXL19-Mediated Ubiquitination and Degradation of the Receptor for IL-33 Limits Pulmonary Inflammation","volume":"13","author":"Zhao","year":"2012","journal-title":"Nat. Immunol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.neurobiolaging.2012.06.015","article-title":"MAPT H1 Haplotype Is Associated with Enhanced \u03b1-Synuclein Deposition in Dementia with Lewy Bodies","volume":"34","author":"Gelpi","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1093\/hmg\/dds161","article-title":"Evidence for a Role of the Rare p.A152T Variant in MAPT in Increasing the Risk for FTD-Spectrum and Alzheimer\u2019s Diseases","volume":"21","author":"Coppola","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"100316","DOI":"10.1016\/j.xgen.2023.100316","article-title":"Genome-Wide Structural Variant Analysis Identifies Risk Loci for Non-Alzheimer\u2019s Dementias","volume":"3","author":"Kaivola","year":"2023","journal-title":"Cell Genom."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10519-020-10011-1","article-title":"Genetic Inactivation of Two-Pore Channel 1 Impairs Spatial Learning and Memory","volume":"50","author":"Mallmann","year":"2020","journal-title":"Behav. Genet."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1440-1789.2011.01199.x","article-title":"Optineurin in Neurodegenerative Diseases","volume":"31","author":"Osawa","year":"2011","journal-title":"Neuropathology"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00401-015-1436-x","article-title":"Whole-Genome Sequencing Reveals Important Role for TBK1 and OPTN Mutations in Frontotemporal Lobar Degeneration without Motor Neuron Disease","volume":"130","author":"Pottier","year":"2015","journal-title":"Acta Neuropathol."},{"key":"ref_123","first-page":"228","article-title":"Alzheimer\u2019s Disease: Early Diagnosis and Treatment","volume":"18","author":"Chu","year":"2012","journal-title":"Hong Kong Med. J."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7861\/clinmedicine.16-3-247","article-title":"Drug Treatments in Alzheimer\u2019s Disease","volume":"16","author":"Briggs","year":"2016","journal-title":"Clin. Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/1570159X11311030006","article-title":"Acetylcholinesterase Inhibitors: Pharmacology and Toxicology","volume":"11","year":"2013","journal-title":"Curr. Neuropharmacol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-148-5-200803040-00008","article-title":"Current Pharmacologic Treatment of Dementia: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians","volume":"148","author":"Qaseem","year":"2008","journal-title":"Ann. Intern. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"379","DOI":"10.7326\/0003-4819-148-5-200803040-00009","article-title":"Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline","volume":"148","author":"Raina","year":"2008","journal-title":"Ann. Intern. Med."},{"key":"ref_128","first-page":"v53","article-title":"Treatment of Dementia","volume":"76","author":"Overshott","year":"2005","journal-title":"Neurol. Pract."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1001\/archneur.60.12.1745","article-title":"Cortical Cholinergic Function Is More Severely Affected in Parkinsonian Dementia than in Alzheimer Disease: An in Vivo Positron Emission Tomographic Study","volume":"60","author":"Bohnen","year":"2003","journal-title":"Arch. Neurol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1212\/WNL.54.2.407","article-title":"Cholinergic Dysfunction in Diseases with Lewy Bodies","volume":"54","author":"Tiraboschi","year":"2000","journal-title":"Neurology"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1212\/01.wnl.0000344650.95823.03","article-title":"Donepezil Treatment of Patients with MCI: A 48-Week Randomized, Placebo-Controlled Trial","volume":"72","author":"Doody","year":"2009","journal-title":"Neurology"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.biopha.2008.02.005","article-title":"Current Approaches in the Treatment of Alzheimer\u2019s Disease","volume":"62","author":"Shah","year":"2008","journal-title":"Biomed. Pharmacother."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1527-3458.2003.tb00254.x","article-title":"The Neuropharmacological Basis for the Use of Memantine in the Treatment of Alzheimer\u2019s Disease","volume":"9","author":"Rogawski","year":"2003","journal-title":"CNS Drug Rev."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Matsunaga, S., Kishi, T., and Iwata, N. (2015). Memantine Monotherapy for Alzheimer\u2019s Disease: A Systematic Review and Meta-Analysis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0123289"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3233\/JAD-170424","article-title":"Memantine for Alzheimer\u2019s Disease: An Updated Systematic Review and Meta-Analysis","volume":"60","author":"Kishi","year":"2017","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S1474-4422(07)70195-3","article-title":"Efficacy and Adverse Effects of Cholinesterase Inhibitors and Memantine in Vascular Dementia: A Meta-Analysis of Randomised Controlled Trials","volume":"6","author":"Kavirajan","year":"2007","journal-title":"Lancet Neurol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1161\/01.STR.0000020094.08790.49","article-title":"Efficacy and Safety of Memantine in Patients with Mild to Moderate Vascular Dementia: A Randomized, Placebo-Controlled Trial (MMM 300)","volume":"33","author":"Orgogozo","year":"2002","journal-title":"Stroke"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1136\/jnnp-2014-307659","article-title":"Efficacy and Safety of Cholinesterase Inhibitors and Memantine in Cognitive Impairment in Parkinson\u2019s Disease, Parkinsons Disease Dementia, and Dementia with Lewy Bodies: Systematic Review with Meta-Analysis and Trial Sequential analysis","volume":"86","author":"Wang","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S1474-4422(09)70146-2","article-title":"Memantine in Patients with Parkinson\u2019s Disease Dementia or Dementia with Lewy Bodies: A Double-Blind, Placebo-Controlled, Multicentre Trial","volume":"8","author":"Aarsland","year":"2009","journal-title":"Lancet Neurol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"e01831","DOI":"10.1002\/brb3.1831","article-title":"Memantine, Donepezil, or Combination Therapy-What Is the Best Therapy for Alzheimer\u2019s Disease? A Network Meta-Analysis","volume":"10","author":"Guo","year":"2020","journal-title":"Brain Behav."},{"key":"ref_141","first-page":"31925","article-title":"Aducanumab, a Novel Anti-Amyloid Monoclonal Antibody, for the Treatment of Alzheimer\u2019s Disease: A Comprehensive Review","volume":"10","author":"Haddad","year":"2022","journal-title":"Health Psychol. Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11910-021-01125-y","article-title":"Critical Appraisal of Amyloid Lowering Agents in AD","volume":"21","author":"Decourt","year":"2021","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The Antibody Aducanumab Reduces A\u03b2 Plaques in Alzheimer\u2019s Disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/alz.12286","article-title":"ENGAGE and EMERGE: Truth and Consequences?","volume":"17","author":"Kuller","year":"2021","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.trci.2019.06.005","article-title":"Disease Severity and Minimal Clinically Important Differences in Clinical Outcome Assessments for Alzheimer\u2019s Disease Clinical Trials","volume":"5","author":"Andrews","year":"2019","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1001\/jama.2021.3854","article-title":"Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility","volume":"325","author":"Alexander","year":"2021","journal-title":"JAMA"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A Randomized, Double-Blind, Phase 2b Proof-of-Concept Clinical Trial in Early Alzheimer\u2019s Disease with Lecanemab, an Anti-A\u03b2 Protofibril Antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer\u2019s Disease","volume":"388","author":"Swanson","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13195-016-0181-2","article-title":"Safety and Tolerability of BAN2401\u2014A Clinical Study in Alzheimer\u2019s Disease with a Protofibril Selective A\u03b2 Antibody","volume":"8","author":"Logovinsky","year":"2016","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1212\/WNL.54.12.2269","article-title":"A 5-Month, Randomized, Placebo-Controlled Trial of Galantamine in AD. The Galantamine USA-10 Study Group","volume":"54","author":"Tariot","year":"2000","journal-title":"Neurology"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fnins.2016.00177","article-title":"One for All? Hitting Multiple Alzheimer\u2019s Disease Targets with One Drug","volume":"10","author":"Hughes","year":"2016","journal-title":"Front. Neurosci."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1021\/jm0603015","article-title":"The Physicochemical Challenges of Designing Multiple Ligands","volume":"49","author":"Morphy","year":"2006","journal-title":"J. Med. Chem."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.tips.2004.11.007","article-title":"Multi-Functional Drugs for Various CNS Targets in the Treatment of Neurodegenerative Disorders","volume":"26","author":"Youdim","year":"2005","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/jama.281.15.1433","article-title":"Challenging the Cholinergic Hypothesis in Alzheimer Disease","volume":"281","author":"Davies","year":"1999","journal-title":"JAMA"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.2174\/092986707782023217","article-title":"Recent Developments in Cholinesterases Inhibitors for Alzheimers Disease Treatment","volume":"14","author":"Musial","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1756-6606-4-3","article-title":"APP Processing in Alzheimer\u2019s Disease","volume":"4","author":"Zhang","year":"2011","journal-title":"Mol. Brain"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3389\/fnins.2016.00243","article-title":"CB2 Cannabinoid Receptor As Potential Target against Alzheimer\u2019s Disease","volume":"10","author":"Aso","year":"2016","journal-title":"Front. Neurosci."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"781","DOI":"10.4155\/fmc-2017-0031","article-title":"Modulating 5-HT4 and 5-HT6 Receptors in Alzheimer\u2019s Disease Treatment","volume":"9","author":"Lalut","year":"2017","journal-title":"Future Med. Chem."},{"key":"ref_160","unstructured":"M\u00f6ssner, R., Schmitt, A., Syagailo, Y., Gerlach, M., Riederer, P., and Lesch, K.P. (2000). Advances in Research on Neurodegeneration, Springer."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/bcp.13048","article-title":"Cardiovascular Effects of Cyclooxygenase-2 Inhibitors: A Mechanistic and Clinical Perspective","volume":"82","author":"Patrono","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12974-020-01742-3","article-title":"Role of Dietary Fatty Acids in Microglial Polarization in Alzheimer\u2019s Disease","volume":"17","author":"Desale","year":"2020","journal-title":"J. Neuroinflamm."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"120111","DOI":"10.1016\/j.lfs.2021.120111","article-title":"Nrf2\/Keap1\/ARE Signaling: Towards Specific Regulation","volume":"291","author":"Ulasov","year":"2022","journal-title":"Life Sci."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ejmech.2014.10.018","article-title":"Design, Synthesis, and Biological Evaluation of 2-Arylethenylquinoline Derivatives as Multifunctional Agents for the Treatment of Alzheimer\u2019s Disease","volume":"89","author":"Wang","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.pneurobio.2015.12.003","article-title":"Multitarget Compounds Bearing Tacrine- and Donepezil-like Structural and Functional Motifs for the Potential Treatment of Alzheimer\u2019s Disease","volume":"151","author":"Ismaili","year":"2017","journal-title":"Prog. Neurobiol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3389\/fnins.2016.00205","article-title":"Multi-Target Directed Donepezil-Like Ligands for Alzheimer\u2019s Disease","volume":"10","author":"Unzeta","year":"2016","journal-title":"Front. Neurosci."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1016\/j.bmc.2014.07.009","article-title":"Design, Synthesis and Evaluation of Rivastigmine and Curcumin Hybrids as Site-Activated Multitarget-Directed Ligands for Alzheimer\u2019s Disease Therapy","volume":"22","author":"Li","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Mazzanti, G., and Di Giacomo, S. (2016). Curcumin and Resveratrol in the Management of Cognitive Disorders: What Is the Clinical Evidence?. Molecules, 21.","DOI":"10.3390\/molecules21091243"},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Cheong, S.L., Tiew, J.K., Fong, Y.H., Leong, H.W., Chan, Y.M., Chan, Z.L., and Kong, E.W.J. (2022). Current Pharmacotherapy and Multi-Target Approaches for Alzheimer\u2019s Disease. Pharmaceuticals, 15.","DOI":"10.3390\/ph15121560"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1192\/apt.10.3.171","article-title":"Non-Pharmacological Interventions in Dementia","volume":"10","author":"Douglas","year":"2004","journal-title":"Adv. Psychiatr. Treat."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1017\/S1041610297003943","article-title":"Behavioral and Psychological Signs and Symptoms of Dementia: A Consensus Statement on Current Knowledge and Implications for Research and Treatment","volume":"8","author":"Finkel","year":"1996","journal-title":"Int. Psychogeriatr."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/1756285617712979","article-title":"Best Practice in the Management of Behavioural and Psychological Symptoms of Dementia","volume":"10","author":"Tible","year":"2017","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11920-019-1049-5","article-title":"Management of Behavioral and Psychological Symptoms of Dementia","volume":"21","author":"Bessey","year":"2019","journal-title":"Curr. Psychiatry Rep."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"679","DOI":"10.12740\/PP\/64477","article-title":"Treatment of Behavioral and Psychological Symptoms of Dementia: A Systematic Review","volume":"50","author":"Preuss","year":"2016","journal-title":"Psychiatr. Pol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1080\/14737175.2022.2112668","article-title":"Tailoring the Therapeutic Interventions for Behavioral and Psychological Symptoms of Dementia","volume":"22","author":"Vuic","year":"2022","journal-title":"Expert Rev. Neurother."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1176\/appi.ajp.2012.11101529","article-title":"Meta-Analysis of Nonpharmacological Interventions for Neuropsychiatric Symptoms of Dementia","volume":"169","author":"Brodaty","year":"2012","journal-title":"Am. J. Psychiatry"},{"key":"ref_177","first-page":"116","article-title":"Non-Pharmacologic Interventions for Persons with Dementia","volume":"114","author":"Stewart","year":"2017","journal-title":"Mo. Med."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"23888","DOI":"10.3402\/qhw.v9.23888","article-title":"Sensory Stimulation\u2014A Way of Creating Mutual Relations in Dementia Care","volume":"9","author":"Lykkeslet","year":"2014","journal-title":"Int. J. Qual. Stud. Health Well-Being"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/(SICI)1099-1166(200002)15:2<141::AID-GPS92>3.0.CO;2-5","article-title":"The Effects of Emotion-Oriented Approaches in the Care for Persons Suffering from Dementia: A Review of the Literature","volume":"15","author":"Finnema","year":"2000","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_180","unstructured":"D\u2019Onofrio, G., Sancarlo, D., Seripa, D., Ricciardi, F., Giuliani, F., Panza, F., and Greco, A. (2016). Update on Dementia, IntechOpen."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"62","DOI":"10.5005\/jp-journals-10067-0038","article-title":"Nonpharmacological Management of Dementia: A Review","volume":"13","author":"Lodha","year":"2019","journal-title":"Indian J. Priv. Psychiatry"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1017\/S1041610200007274","article-title":"Application of Psychosocial Interventions for Treating Behavioral and Psychological Symptoms of Dementia","volume":"12","author":"Burgio","year":"2000","journal-title":"Int. Psychogeriatr."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000316119","article-title":"Nonpharmacological Therapies in Alzheimer\u2019s Disease: A Systematic Review of Efficacy","volume":"30","author":"Reisberg","year":"2010","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000101499","article-title":"Meta-Analysis of the Effectiveness of Atypical Antipsychotics for the Treatment of Behavioural Problems in Persons with Dementia","volume":"76","author":"Yury","year":"2007","journal-title":"Psychother. Psychosom."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa061240","article-title":"Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer\u2019s Disease","volume":"355","author":"Schneider","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1159\/000110738","article-title":"Neuropsychiatric Syndromes in Dementia. Results from the European Alzheimer Disease Consortium: Part I","volume":"24","author":"Aalten","year":"2007","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1177\/1471301218813234","article-title":"Non-Pharmacological Interventions for People with Dementia: A Review of Reviews","volume":"19","author":"Meyer","year":"2020","journal-title":"Dementia"},{"key":"ref_188","first-page":"884","article-title":"Clinical Practice Guidelines and Principles of Care for People with Dementia in Australia","volume":"45","author":"Dyer","year":"2016","journal-title":"Aust. Fam. Physician"},{"key":"ref_189","unstructured":"National Collaborating Centre for Mental Health (2007). Dementia: A NICE-SCIE Guideline on Supporting People with Dementia and Their Carers in Health and Social Care, British Psychological Society (UK)."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/gps.4572","article-title":"Impact of Antipsychotic Review and Non-Pharmacological Intervention on Health-Related Quality of Life in People with Dementia Living in Care Homes: WHELD-a Factorial Cluster Randomised Controlled Trial","volume":"32","author":"Ballard","year":"2017","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_191","first-page":"CD003477","article-title":"Music-Based Therapeutic Interventions for People with Dementia","volume":"5","author":"Bruinsma","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_192","first-page":"CD009125","article-title":"Psychological Treatments for Depression and Anxiety in Dementia and Mild Cognitive Impairment","volume":"2014","author":"Orgeta","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40262-013-0038-9","article-title":"Pharmacodynamic, Pharmacokinetic and Pharmacogenetic Aspects of Drugs Used in the Treatment of Alzheimer\u2019s Disease","volume":"52","author":"Noetzli","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2165\/11201020-000000000-00000","article-title":"Memantine","volume":"23","author":"McKeage","year":"2009","journal-title":"CNS Drugs"},{"key":"ref_195","first-page":"303","article-title":"Donepezil in Alzheimer\u2019s Disease: From Conventional Trials to Pharmacogenetics","volume":"3","author":"Cacabelos","year":"2007","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Ovejero-Benito, M.C., Ochoa, D., Enrique-Benedito, T., Del Peso-Casado, M., Zubiaur, P., Navares, M., Rom\u00e1n, M., and Abad-Santos, F. (2022). Pharmacogenetics of Donepezil and Memantine in Healthy Subjects. J. Pers. Med., 12.","DOI":"10.3390\/jpm12050788"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1212\/WNL.0b013e3181b6bbe3","article-title":"Effect of a CYP2D6 Polymorphism on the Efficacy of Donepezil in Patients with Alzheimer Disease","volume":"73","author":"Pilotto","year":"2009","journal-title":"Neurology"},{"key":"ref_198","first-page":"1029","article-title":"Influence of Rs1080985 Single Nucleotide Polymorphism of the CYP2D6 Gene on Response to Treatment with Donepezil in Patients with Alzheimer\u2019s Disease","volume":"9","author":"Wolkow","year":"2013","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.2147\/DDDT.S247259","article-title":"Therapeutic Drug Monitoring of Rivastigmine and Donepezil Under Consideration of CYP2D6 Genotype-Dependent Metabolism of Donepezil","volume":"14","author":"Ortner","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/FTD.0000000000000823","article-title":"Impact of CYP2D6, CYP3A5, and ABCB1 Polymorphisms on Plasma Concentrations of Donepezil and Its Metabolite in Patients with Alzheimer Disease","volume":"43","author":"Kagawa","year":"2021","journal-title":"Ther. Drug Monit."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/FPC.0b013e32833f984c","article-title":"Role of Cytochrome P4502D6 Functional Polymorphisms in the Efficacy of Donepezil in Patients with Alzheimer\u2019s Disease","volume":"21","author":"Seripa","year":"2011","journal-title":"Pharmacogenet. Genom."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/bcp.12325","article-title":"Population Pharmacokinetic Approach to Evaluate the Effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 Genotypes on Donepezil Clearance","volume":"78","author":"Noetzli","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"934","DOI":"10.3389\/fphar.2020.00934","article-title":"Gene Polymorphisms Affecting the Pharmacokinetics and Pharmacodynamics of Donepezil Efficacy","volume":"11","author":"Lu","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00228-006-0168-1","article-title":"Impact of the CYP2D6 Polymorphism on Steady-State Plasma Concentrations and Clinical Outcome of Donepezil in Alzheimer\u2019s Disease Patients","volume":"62","author":"Varsaldi","year":"2006","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/00008571-200110000-00004","article-title":"Comprehensive Analysis of the Genetic Factors Determining Expression and Function of Hepatic CYP2D6","volume":"11","author":"Zanger","year":"2001","journal-title":"Pharmacogenetics"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/MAJ.0b013e318255a8f9","article-title":"Effect of CYP2D6*10 and APOE Polymorphisms on the Efficacy of Donepezil in Patients with Alzheimer\u2019s Disease","volume":"345","author":"Zhong","year":"2013","journal-title":"Am. J. Med. Sci."},{"key":"ref_207","first-page":"209","article-title":"Influence of CYP2D6, CYP3A5, ABCB1, APOE Polymorphisms and Nongenetic Factors on Donepezil Treatment in Patients with Alzheimer\u2019s Disease and Vascular Dementia","volume":"12","author":"Yaowaluk","year":"2019","journal-title":"Pharmgenom. Pers. Med."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.bmcl.2014.11.046","article-title":"Investigating the Binding Interactions of the Anti-Alzheimer\u2019s Drug Donepezil with CYP3A4 and P-Glycoprotein","volume":"25","author":"Edginton","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00228-010-0883-5","article-title":"Do CYP3A and ABCB1 Genotypes Influence the Plasma Concentration and Clinical Outcome of Donepezil Treatment?","volume":"67","author":"Magliulo","year":"2011","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1177\/1533317519848237","article-title":"Effect of CYP2D6 and CYP3A4 Genotypes on the Efficacy of Cholinesterase Inhibitors in Southern Chinese Patients with Alzheimer\u2019s Disease","volume":"34","author":"Ma","year":"2019","journal-title":"Am. J. Alzheimer\u2019s Dis. Other Demen."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","article-title":"Apolipoprotein E and Alzheimer Disease: Risk, Mechanisms and Therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000087371","article-title":"Apolipoprotein E Epsilon4 Allele Differentiates the Clinical Response to Donepezil in Alzheimer\u2019s Disease","volume":"20","author":"Bizzarro","year":"2005","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1159\/000124752","article-title":"Effect of ApoE Genotype on Response to Donepezil in Patients with Alzheimer\u2019s Disease","volume":"25","author":"Choi","year":"2008","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0924-977X(02)00013-5","article-title":"ApoE Genotype Influences the Biological Effect of Donepezil on APP Metabolism in Alzheimer Disease: Evidence from a Peripheral Model","volume":"12","author":"Borroni","year":"2002","journal-title":"Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2165\/11310960-000000000-00000","article-title":"Effects of Donepezil, Galantamine and Rivastigmine in 938 Italian Patients with Alzheimer\u2019s Disease: A Prospective, Observational Study","volume":"24","author":"Santoro","year":"2010","journal-title":"CNS Drugs"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3233\/JAD-142589","article-title":"APOE-\u03b54 Carrier Status and Donepezil Response in Patients with Alzheimer\u2019s Disease","volume":"47","author":"Waring","year":"2015","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.neulet.2015.12.062","article-title":"The Roles of Apolipoprotein E3 and CYP2D6 (Rs1065852) Gene Polymorphisms in the Predictability of Responses to Individualized Therapy with Donepezil in Han Chinese Patients with Alzheimer\u2019s Disease","volume":"614","author":"Lu","year":"2016","journal-title":"Neurosci. Lett."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/j.1755-5949.2010.00189.x","article-title":"Genomics and Pharmacogenomics of Dementia","volume":"17","author":"Cacabelos","year":"2011","journal-title":"CNS Neurosci. Ther."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainresbull.2018.03.014","article-title":"Association between ABCA1 Gene Polymorphisms and the Therapeutic Response to Donepezil Therapy in Han Chinese Patients with Alzheimer\u2019s Disease","volume":"140","author":"Lu","year":"2018","journal-title":"Brain Res. Bull."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/advances\/nmab145","article-title":"Perspective: Estrogen and the Risk of Cognitive Decline: A Missing Choline(Rgic) Link?","volume":"13","author":"Bortz","year":"2022","journal-title":"Adv. Nutr."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/gps.4043","article-title":"Sex and ESR1 Genotype May Influence the Response to Treatment with Donepezil and Rivastigmine in Patients with Alzheimer\u2019s Disease","volume":"29","author":"Scacchi","year":"2014","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.bcp.2018.01.044","article-title":"Cholinesterases and the Fine Line between Poison and Remedy","volume":"153","author":"Pope","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"17170","DOI":"10.1074\/jbc.M109.004952","article-title":"The Butyrylcholinesterase K Variant Confers Structurally Derived Risks for Alzheimer Pathology","volume":"284","author":"Podoly","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3233\/JAD-160562","article-title":"Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment","volume":"56","author":"Sokolow","year":"2017","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/01.fpc.0000220573.05714.ac","article-title":"Effect of Butyrylcholinesterase Genotype on the Response to Rivastigmine or Donepezil in Younger Patients with Alzheimer\u2019s Disease","volume":"16","author":"Blesa","year":"2006","journal-title":"Pharmacogenet. Genom."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/ajmg.b.30846","article-title":"Variability of AChE, BChE, and ChAT Genes in the Late-Onset Form of Alzheimer\u2019s Disease and Relationships with Response to Treatment with Donepezil and Rivastigmine","volume":"150","author":"Scacchi","year":"2009","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3233\/JAD-160373","article-title":"Butyrylcholinesterase K and Apolipoprotein E-\u03b54 Reduce the Age of Onset of Alzheimer\u2019s Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects","volume":"54","author":"Pelleieux","year":"2016","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1055\/s-0035-1545300","article-title":"Association of the Choline Acetyltransferase Gene with Responsiveness to Acetylcholinesterase Inhibitors in Alzheimer\u2019s Disease","volume":"48","author":"Yoon","year":"2015","journal-title":"Pharmacopsychiatry"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/01.fpc.0000189799.88596.04","article-title":"A Single Nucleotide Polymorphism in CHAT Influences Response to Acetylcholinesterase Inhibitors in Alzheimer\u2019s Disease","volume":"16","author":"Harold","year":"2006","journal-title":"Pharmacogenet. Genom."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"168","DOI":"10.9758\/cpn.2015.13.2.168","article-title":"The Effect of Choline Acetyltransferase Genotype on Donepezil Treatment Response in Patients with Alzheimer\u2019s Disease","volume":"13","author":"Lee","year":"2015","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/1533317514539540","article-title":"Effect of APOE and CHRNA7 Genotypes on the Cognitive Response to Cholinesterase Inhibitor Treatment at Different Stages of Alzheimer\u2019s Disease","volume":"30","author":"Braga","year":"2015","journal-title":"Am. J. Alzheimer\u2019s Dis. Other Demen."},{"key":"ref_232","doi-asserted-by":"crossref","unstructured":"Weng, P.-H., Chen, J.-H., Chen, T.-F., Sun, Y., Wen, L.-L., Yip, P.-K., Chu, Y.-M., and Chen, Y.-C. (2013). CHRNA7 Polymorphisms and Response to Cholinesterase Inhibitors in Alzheimer\u2019s Disease. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0084059"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.3233\/JAD-160074","article-title":"CHRNA7 Gene and Response to Cholinesterase Inhibitors in an Italian Cohort of Alzheimer\u2019s Disease Patients","volume":"52","author":"Clarelli","year":"2016","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_234","doi-asserted-by":"crossref","unstructured":"Khalaf, F.K., Connolly, J., Khatib-Shahidi, B., Albehadili, A., Tassavvor, I., Ranabothu, M., Eid, N., Dube, P., Khouri, S.J., and Malhotra, D. (2023). Paraoxonases at the Heart of Neurological Disorders. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24086881"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/ng0193-73","article-title":"The Molecular Basis of the Human Serum Paraoxonase Activity Polymorphism","volume":"3","author":"Humbert","year":"1993","journal-title":"Nat. Genet."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.neulet.2005.03.027","article-title":"Responsiveness to Cholinesterase Inhibitors in Alzheimer\u2019s Disease: A Possible Role for the 192 Q\/R Polymorphism of the PON-1 Gene","volume":"382","author":"Pola","year":"2005","journal-title":"Neurosci. Lett."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000342927","article-title":"Response to Rivastigmine Transdermal Patch or Memantine plus Rivastigmine Patch Is Affected by Apolipoprotein E Genotype in Alzheimer Patients","volume":"34","author":"Han","year":"2012","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/01.wad.0000213880.93665.c7","article-title":"Relationship between the Efficacy of Rivastigmine and Apolipoprotein E (Epsilon4) in Patients with Mild to Moderately Severe Alzheimer Disease","volume":"20","author":"Blesa","year":"2006","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/sj.tpj.6500267","article-title":"Differential Qualitative Responses to Rivastigmine in APOE Epsilon 4 Carriers and Noncarriers","volume":"4","author":"Farlow","year":"2004","journal-title":"Pharmacogenom. J."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000366198","article-title":"Effect of Rivastigmine or Memantine Add-on Therapy Is Affected by Butyrylcholinesterase Genotype in Patients with Probable Alzheimer\u2019s Disease","volume":"73","author":"Han","year":"2015","journal-title":"Eur. Neurol."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/sj.mp.4001101","article-title":"Regulatory Region Variability in the Human Presenilin-2 (PSEN2) Gene: Potential Contribution to the Gene Activity and Risk for AD","volume":"7","author":"Riazanskaia","year":"2002","journal-title":"Mol. Psychiatry"},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000329514","article-title":"Pharmacogenetic Study on the Effect of Rivastigmine on PS2 and APOE Genes in Iranian Alzheimer Patients","volume":"1","author":"Zamani","year":"2011","journal-title":"Dement. Geriatr. Cogn. Dis. Extra"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1006\/bbrc.2000.2795","article-title":"Isolation and Characterization of the Human UGT2B7 Gene","volume":"272","author":"Carrier","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/FPC.0b013e3283037fe4","article-title":"Single Nucleotide Polymorphism Discovery and Functional Assessment of Variation in the UDP-Glucuronosyltransferase 2B7 Gene","volume":"18","author":"Innocenti","year":"2008","journal-title":"Pharmacogenet. Genom."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/cns.12036","article-title":"Clinical Effectiveness of Rivastigmine Monotherapy and Combination Therapy in Alzheimer\u2019s Patients","volume":"19","author":"Sonali","year":"2013","journal-title":"CNS Neurosci. Ther."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.2174\/1389450116666151001111826","article-title":"Effect of Genetic Polymorphisms (SNPs) in CHRNA7 Gene on Response to Acetylcholinesterase Inhibitors (AChEI) in Patients with Alzheimer\u2019s Disease","volume":"18","author":"Russo","year":"2017","journal-title":"Curr. Drug Targets"},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1517\/17425255.2011.547474","article-title":"Role of Organic Cation Transporters in Drug-Induced Toxicity","volume":"7","author":"Ciarimboli","year":"2011","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40262-013-0032-2","article-title":"Population Pharmacokinetic Study of Memantine: Effects of Clinical and Genetic Factors","volume":"52","author":"Noetzli","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"27078","DOI":"10.1074\/jbc.M110.109678","article-title":"Colon OCTN2 Gene Expression Is Up-Regulated by Peroxisome Proliferator-Activated Receptor Gamma in Humans and Mice and Contributes to Local and Systemic Carnitine Homeostasis","volume":"285","author":"Petillo","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2174\/1389200054633826","article-title":"Regulation of Hepatic Transporters by Xenobiotic Receptors","volume":"6","author":"Klaassen","year":"2005","journal-title":"Curr. Drug Metab."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1124\/dmd.107.015842","article-title":"Effect of Pregnane X Receptor Ligand on Pharmacokinetics of Substrates of Organic Cation Transporter Oct1 in Rats","volume":"35","author":"Maeda","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1517\/17425255.4.7.895","article-title":"The Pregnane X Receptor: From Bench to Bedside","volume":"4","author":"Ma","year":"2008","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13024-022-00574-4","article-title":"ApoE in Alzheimer\u2019s Disease: Pathophysiology and Therapeutic Strategies","volume":"17","author":"Raulin","year":"2022","journal-title":"Mol. Neurodegener."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.3390\/ph3103040","article-title":"Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants","volume":"3","author":"Cacabelos","year":"2010","journal-title":"Pharmaceuticals"},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"1029073","DOI":"10.3389\/fphar.2022.1029073","article-title":"Physiologically Based Pharmacokinetic (PBPK) Modeling of the Role of CYP2D6 Polymorphism for Metabolic Phenotyping with Dextromethorphan","volume":"13","author":"Grzegorzewski","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2174\/156720507781788846","article-title":"Pharmacogenetic Aspects of Therapy with Cholinesterase Inhibitors: The Role of CYP2D6 in Alzheimer\u2019s Disease Pharmacogenetics","volume":"4","author":"Cacabelos","year":"2007","journal-title":"Curr. Alzheimer Res."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1034\/j.1600-0404.2000.00302.x","article-title":"A Pharmacogenomic Approach to Alzheimer\u2019s Disease","volume":"176","author":"Cacabelos","year":"2000","journal-title":"Acta Neurol. Scand. Suppl."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3233\/JAD-170786","article-title":"Medical Comorbidity in Alzheimer\u2019s Disease: A Nested Case-Control Study","volume":"63","author":"Wang","year":"2018","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"853","DOI":"10.2165\/00002512-200118110-00006","article-title":"Cholinergic Adverse Effects of Cholinesterase Inhibitors in Alzheimer\u2019s Disease: Epidemiology and Management","volume":"18","author":"Gauthier","year":"2001","journal-title":"Drugs Aging"},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2174\/157015908783769671","article-title":"Pharmacodynamics of Memantine: An Update","volume":"6","author":"Rammes","year":"2008","journal-title":"Curr. Neuropharmacol."},{"key":"ref_261","first-page":"398","article-title":"Aducanumab: Appropriate Use Recommendations","volume":"8","author":"Cummings","year":"2021","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"ref_262","first-page":"362","article-title":"Lecanemab: Appropriate Use Recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"e069402","DOI":"10.1002\/alz.069402","article-title":"Modeled Impact of APOE4 Genotype on ARIA-E Incidence in Patients Treated With Lecanemab","volume":"18","author":"Reyderman","year":"2022","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.3389\/fphar.2019.01062","article-title":"Behavioral and Psychiatric Symptoms of Dementia and Rate of Decline in Alzheimer\u2019s Disease","volume":"10","author":"Gottesman","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1586\/erm.09.42","article-title":"Pharmacogenomics and Therapeutic Strategies for Dementia","volume":"9","author":"Cacabelos","year":"2009","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/23808993.2020.1738217","article-title":"Pharmacogenomics of Drugs Used to Treat Brain Disorders","volume":"5","author":"Cacabelos","year":"2020","journal-title":"Expert Rev. Precis. Med. Drug Dev."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1016\/j.neuron.2021.09.011","article-title":"Pharmacogenomics: A Road Ahead for Precision Medicine in Psychiatry","volume":"109","author":"Owen","year":"2021","journal-title":"Neuron"},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"57","DOI":"10.18662\/brain\/11.1Sup2\/39","article-title":"Pharmacogenomics in Psychiatric Disorders","volume":"11","author":"Tauser","year":"2020","journal-title":"Brain Resaerch Artif. Intell. Neurosci."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2217\/1745509X.1.2.303","article-title":"Pharmacogenomics, Nutrigenomics and Therapeutic Optimization in Alzheimer\u2019s Disease","volume":"1","author":"Cacabelos","year":"2005","journal-title":"Aging Health"},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1002\/gps.5556","article-title":"Prevalence of Depression, Anxiety, and Apathy Symptoms across Dementia Stages: A Systematic Review and Meta-Analysis","volume":"36","author":"Leung","year":"2021","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13195-016-0171-4","article-title":"A Longitudinal Study of Anxiety and Cognitive Decline in Dementia with Lewy Bodies and Alzheimer\u2019s Disease","volume":"8","author":"Breitve","year":"2016","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3233\/JAD-161287","article-title":"Is Sleep Disruption a Risk Factor for Alzheimer\u2019s Disease?","volume":"58","author":"Macedo","year":"2017","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/psyg.12069","article-title":"Sleep Disturbances and Dementia","volume":"15","author":"Cipriani","year":"2015","journal-title":"Psychogeriatrics"},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.5665\/sleep.2802","article-title":"Sleep Fragmentation and the Risk of Incident Alzheimer\u2019s Disease and Cognitive Decline in Older Persons","volume":"36","author":"Lim","year":"2013","journal-title":"Sleep"},{"key":"ref_275","first-page":"1","article-title":"Physician Office Visits at Which Benzodiazepines Were Prescribed: Findings from 2014\u20132016 National Ambulatory Medical Care Survey","volume":"137","author":"Santo","year":"2020","journal-title":"Natl. Health Stat. Rep."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3389\/fpsyt.2020.00755","article-title":"The Effects of Benzodiazepine Use and Abuse on Cognition in the Elders: A Systematic Review and Meta-Analysis of Comparative Studies","volume":"11","author":"Liu","year":"2020","journal-title":"Front. Psychiatry"},{"key":"ref_277","first-page":"214","article-title":"Benzodiazepine Pharmacology and Central Nervous System-Mediated Effects","volume":"13","author":"Griffin","year":"2013","journal-title":"Ochsner J."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00702-009-0229-6","article-title":"Pharmacogenetics of Anxiolytic Drugs","volume":"116","author":"Tiwari","year":"2009","journal-title":"J. Neural Transm."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1365-2710.2007.00829.x","article-title":"Effects of Genetic Polymorphism of Cytochrome P450 Enzymes on the Pharmacokinetics of Benzodiazepines","volume":"32","author":"Fukasawa","year":"2007","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_280","unstructured":"Pratt, V., Scott, S., Pirmohamed, M., Esquivel, B., Kattman, B., and Malheiro, A. (2012). Diazepam Therapy and CYP2C19 Genotype, Medical Genetics Summaries [Internet]."},{"key":"ref_281","doi-asserted-by":"crossref","unstructured":"Zubiaur, P., Figueiredo-Tor, L., Villapalos-Garc\u00eda, G., Soria-Chacartegui, P., Navares-G\u00f3mez, M., Novalbos, J., Matas, M., Calleja, S., Mej\u00eda-Abril, G., and Rom\u00e1n, M. (2022). Association between CYP2C19 and CYP2B6 Phenotypes and the Pharmacokinetics and Safety of Diazepam. Biomed. Pharmacother., 155.","DOI":"10.1016\/j.biopha.2022.113747"},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jamda.2016.09.021","article-title":"CYP2C9 Genotypes Modify Benzodiazepine-Related Fall Risk: Original Results from Three Studies with Meta-Analysis","volume":"18","author":"Ham","year":"2017","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/cpt.910","article-title":"The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database","volume":"103","author":"Gaedigk","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/cpt.597","article-title":"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update","volume":"102","author":"Hicks","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_285","first-page":"20190026","article-title":"How Do CYP2C19*2 and CYP2C19*17 Genetic Polymorphisms Affect the Efficacy and Safety of Diazepam in Patients with Alcohol Withdrawal Syndrome?","volume":"35","author":"Skryabin","year":"2020","journal-title":"Drug Metab. Pers. Ther."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1177\/0018578720931756","article-title":"Effects of CYP2C19*17 Genetic Polymorphisms on the Steady-State Concentration of Diazepam in Patients with Alcohol Withdrawal Syndrome","volume":"56","author":"Skryabin","year":"2021","journal-title":"Hosp. Pharm."},{"key":"ref_287","doi-asserted-by":"crossref","unstructured":"Ho, T.T., Noble, M., Tran, B.A., Sunjic, K., Gupta, S.V., Turgeon, J., and Crutchley, R.D. (2023). Clinical Impact of the CYP2C19 Gene on Diazepam for the Management of Alcohol Withdrawal Syndrome. J. Pers. Med., 13.","DOI":"10.3390\/jpm13020285"},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/clpt.1989.40","article-title":"Importance of Genetic Factors in the Regulation of Diazepam Metabolism: Relationship to S-Mephenytoin, but Not Debrisoquin, Hydroxylation Phenotype","volume":"45","author":"Bertilsson","year":"1989","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0009-9236(99)90075-9","article-title":"Effect of the Gene Dosage of CgammaP2C19 on Diazepam Metabolism in Chinese Subjects","volume":"66","author":"Qin","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2217\/14622416.9.5.527","article-title":"Impact of CYP2C19 Polymorphisms on the Efficacy of Clobazam Therapy","volume":"9","author":"Seo","year":"2008","journal-title":"Pharmacogenomics"},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1177\/19418744231189078","article-title":"Elevations in Norclobazam Concentrations and Altered Mental Status in CYP2C19 Poor Metabolizer Phenotype: A Case Report","volume":"13","author":"Phillips","year":"2023","journal-title":"Neurohospitalist"},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/epi4.12717","article-title":"A Real-Life Pilot Study of the Clinical Application of Pharmacogenomics Testing on Saliva in Epilepsy","volume":"8","author":"Riva","year":"2023","journal-title":"Epilepsia Open"},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1365-2125.2009.03578.x","article-title":"Pharmacogenetics of CYP2C19: Functional and Clinical Implications of a New Variant CYP2C19*17","volume":"69","author":"Girard","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_294","doi-asserted-by":"crossref","unstructured":"Denisov, I.G., Grinkova, Y.V., McLean, M.A., Camp, T., and Sligar, S.G. (2022). Midazolam as a Probe for Heterotropic Drug-Drug Interactions Mediated by CYP3A4. Biomolecules, 12.","DOI":"10.3390\/biom12060853"},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"8015","DOI":"10.1074\/jbc.RA119.007928","article-title":"Active-Site Differences between Substrate-Free and Ritonavir-Bound Cytochrome P450 (CYP) 3A5 Reveal Plasticity Differences between CYP3A5 and CYP3A4","volume":"294","author":"Hsu","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence Diversity in CYP3A Promoters and Characterization of the Genetic Basis of Polymorphic CYP3A5 Expression","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat. Genet."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.clpt.2004.02.005","article-title":"CYP3A5 Genotype and Midazolam Clearance in Australian Patients Receiving Chemotherapy","volume":"75","author":"Wong","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/sj.clpt.6100237","article-title":"Influence of CYP3A5 Genotype on the Pharmacokinetics and Pharmacodynamics of the Cytochrome P4503A Probes Alfentanil and Midazolam","volume":"82","author":"Kharasch","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/00008571-200310000-00003","article-title":"Genotype-Phenotype Associations for Common CYP3A4 and CYP3A5 Variants in the Basal and Induced Metabolism of Midazolam in European- and African-American Men and Women","volume":"13","author":"Floyd","year":"2003","journal-title":"Pharmacogenetics"},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.clpt.2004.11.112","article-title":"Genotype-Phenotype Associations of Cytochrome P450 3A4 and 3A5 Polymorphism with Midazolam Clearance In Vivo","volume":"77","author":"He","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1023\/A:1023433502647","article-title":"Midazolam Exhibits Characteristics of a Highly Permeable P-Glycoprotein Substrate","volume":"20","author":"Rautio","year":"2003","journal-title":"Pharm. Res."},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"16001","DOI":"10.1038\/s41598-019-52517-7","article-title":"Influence of Midazolam-Related Genetic Polymorphism on Conscious Sedation during Upper Gastrointestinal Endoscopy in a Korean Population","volume":"9","author":"Park","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/00003088-198106020-00001","article-title":"Clinical Pharmacokinetics of Oxazepam and Lorazepam","volume":"6","author":"Greenblatt","year":"1981","journal-title":"Clin. Pharmacokinet."},{"key":"ref_304","first-page":"e3133","article-title":"The Relationship of UGT2B15 Pharmacogenetics and Lorazepam for Anxiety","volume":"10","author":"Ching","year":"2018","journal-title":"Cureus"},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1152\/physrev.00058.2017","article-title":"The UDP-Glycosyltransferase (UGT) Superfamily: New Members, New Functions, and Novel Paradigms","volume":"99","author":"Meech","year":"2019","journal-title":"Physiol. Rev."},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.clpt.2005.02.006","article-title":"Effect of the UGT2B15 Genotype on the Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Intravenous Lorazepam in Healthy Volunteers","volume":"77","author":"Chung","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1213\/ANE.0000000000001508","article-title":"Implication of UGT2B15 Genotype Polymorphism on Postoperative Anxiety Levels in Patients Receiving Lorazepam Premedication","volume":"123","author":"Mijderwijk","year":"2016","journal-title":"Anesth. Analg."},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00023210-200721050-00003","article-title":"Use of Non-Benzodiazepine Hypnotics in the Elderly: Are All Agents the Same?","volume":"21","author":"Dolder","year":"2007","journal-title":"CNS Drugs"},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1046\/j.1365-2125.1999.00953.x","article-title":"Zolpidem Metabolism in Vitro: Responsible Cytochromes, Chemical Inhibitors, and in Vivo Correlations","volume":"48","author":"Greenblatt","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.forsciint.2012.08.035","article-title":"CYP3A4 and CYP2C19 Genetic Polymorphisms and Zolpidem Metabolism in the Chinese Han Population: A Pilot Study","volume":"227","author":"Shen","year":"2013","journal-title":"Forensic Sci. Int."},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s12272-018-1065-8","article-title":"Effects of Genetic Polymorphisms of CYP2C19 on the Pharmacokinetics of Zolpidem","volume":"41","author":"Byeon","year":"2018","journal-title":"Arch. Pharm. Res."},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1007\/s12272-020-01250-1","article-title":"Relationship between Plasma Exposure of Zolpidem and CYP2D6 Genotype in Healthy Korean Subjects","volume":"43","author":"Jung","year":"2020","journal-title":"Arch. Pharm. Res."},{"key":"ref_313","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s12272-018-1070-y","article-title":"The Influences of CYP2C9*1\/*3 Genotype on the Pharmacokinetics of Zolpidem","volume":"41","author":"Byeon","year":"2018","journal-title":"Arch. Pharm. Res."},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/nrg1432","article-title":"Pharmacogenetics and Drug Development: The Path to Safer and More Effective Drugs","volume":"5","author":"Roses","year":"2004","journal-title":"Nat. Rev. Genet."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/14\/11\/2048\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:18:28Z","timestamp":1760131108000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/14\/11\/2048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,6]]},"references-count":314,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["genes14112048"],"URL":"https:\/\/doi.org\/10.3390\/genes14112048","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,6]]}}}